Lupin Shares Rose 4% Following Plans for Major U.S. Manufacturing Facility

On October 9, 2025, Lupin share price rose as much as 4%, reaching a day high of ₹1,984.05 at 10:15 AM, after opening at ₹1,915.55 on BSE. The gain in Lupin share price came after the company unveiled plans to build a cutting-edge manufacturing facility in Coral Springs, Florida. This strategic investment aims to bolster the domestic production of critical respiratory medications, particularly for the U.S. market.

Luping to Spend $250 Million

Lupin is committing $250 million over the next five years to this project, with funds allocated across research and development, infrastructure development, and capital expenditures. Once operational, the plant will have the capacity to manufacture more than 25 vital respiratory therapies, including lifesaving albuterol inhalers used by children with asthma and U.S. military personnel both at home and abroad.

The new facility marks a significant milestone in Lupin’s efforts to enhance medicine security and improve health outcomes for families in Florida and across the United States.

“The expansion of Lupin’s footprint in Coral Springs is a core part of our growth strategy. This new state-of-the-art facility will build on our existing presence in Florida, which is home to Lupin’s headquarters and our Advanced Inhalation Research Center. This investment demonstrates Lupin’s commitment to innovation, quality and supply chain reliability and our ability to partner with Florida’s leaders to strengthen America’s medicine security by growing our capacity to produce affordable treatments for patients. We are grateful to Florida’s leadership for their partnership in making this possible,”

Also Read: Senco Gold Shares Fell Over 2% After Releasing Q2 Business Update: Revenue Rose 6.5% YoY

Conclusion

This expansion not only supports Lupin’s goal of strengthening domestic manufacturing and diversifying the pharmaceutical supply chain but also reinforces its standing as a global leader in respiratory care.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in securities market are subject to market risks, read all the related documents carefully before investing.